PMID- 18759642
OWN - NLM
STAT- MEDLINE
DCOM- 20081027
LR  - 20211018
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Linking)
VI  - 18
IP  - 4
DP  - 2008 Aug
TI  - Antipsychotic treatment in child and adolescent first-episode psychosis: a 
      longitudinal naturalistic approach.
PG  - 327-36
LID - 10.1089/cap.2007.0138 [doi]
AB  - OBJECTIVE: The Child and Adolescent First-Episode Psychosis Study (CAFEPS) is a 
      naturalistic longitudinal study of early-onset first psychotic episodes. This 
      report describes the antipsychotic treatment during the first year and compares 
      the most frequently used agents after 6 months. METHODS: Participants were 110 
      patients, aged 9-17 years, with a first psychotic episode attended consecutively 
      at six different centers. The Positive and Negative Symptom Scale (PANSS), 
      Clinical Global Impressions (CGI), Disability Assessment Schedule (DAS), and 
      Global Assessment of Function (GAF) scales were administered at baseline and at 6 
      months and the Udvalg for Kliniske Undersogelser (UKU) Side Effects Rating Scale 
      only at 6 months. RESULTS: Diagnoses at baseline were 38.2% psychotic disorder 
      not otherwise specified, 39.1% schizophrenia-type disorder, 11.8% depressive 
      disorder with psychotic symptoms, and 10.9% bipolar disorder, manic episode with 
      psychotic symptoms. The most frequently used antipsychotic agents were 
      risperidone (n = 50), quetiapine (n = 18), and olanzapine (n = 16). Patients who 
      were prescribed olanzapine or quetiapine had more negative and general symptoms. 
      Using the baseline score as covariate, no significant differences were found in 
      the reductions on any scale in patients treated with risperidone, quetiapine, or 
      olanzapine for 6 months. Weight increase was greater with olanzapine than with 
      risperidone (p = 0.020) or quetiapine (p = 0.040). More neurological side effects 
      appeared with risperidone than with olanzapine (p = 0.022). All side effects were 
      mild or moderate. CONCLUSIONS: Second-generation antipsychotics, especially 
      risperidone, quetiapine, and olanzapine, are the most used in our context in 
      first psychotic episodes in children and adolescents. These three obtain similar 
      clinical improvement, but differ in their side effects.
FAU - Castro-Fornieles, Josefina
AU  - Castro-Fornieles J
AD  - Department of Child and Adolescent Psychiatry and Psychology, Institut Clinic of 
      Neurosciences, IDIBAPS, (Institut d'Investigacions Biomediques August Pi Sunyer), 
      Hospital Clinic Universitario of Barcelona, Spain. jcastro@clinic.ub.es
FAU - Parellada, Mara
AU  - Parellada M
FAU - Soutullo, Cesar A
AU  - Soutullo CA
FAU - Baeza, Immaculada
AU  - Baeza I
FAU - Gonzalez-Pinto, Ana
AU  - Gonzalez-Pinto A
FAU - Graell, Montserrat
AU  - Graell M
FAU - Paya, Beatriz
AU  - Paya B
FAU - Moreno, Dolores
AU  - Moreno D
FAU - de la Serna, Elena
AU  - de la Serna E
FAU - Arango, Celso
AU  - Arango C
LA  - eng
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Dibenzothiazepines)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - L6UH7ZF8HC (Risperidone)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adolescent
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Benzodiazepines/adverse effects/therapeutic use
MH  - Child
MH  - Dibenzothiazepines/adverse effects/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Olanzapine
MH  - *Practice Patterns, Physicians'
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/*drug therapy
MH  - Quetiapine Fumarate
MH  - Risperidone/adverse effects/therapeutic use
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Weight Gain/drug effects
EDAT- 2008/09/02 09:00
MHDA- 2008/10/28 09:00
CRDT- 2008/09/02 09:00
PHST- 2008/09/02 09:00 [pubmed]
PHST- 2008/10/28 09:00 [medline]
PHST- 2008/09/02 09:00 [entrez]
AID - 10.1089/cap.2007.0138 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2008 Aug;18(4):327-36. doi: 
      10.1089/cap.2007.0138.